Canaccord Genuity Reiterates “$28.00” Price Target for Summit Therapeutics PLC (SMMT)
SMMT has been the subject of several other research reports. Needham & Company LLC raised their target price on Summit Therapeutics PLC from $22.00 to $30.00 and gave the stock a buy rating in a research report on Tuesday, October 4th. Zacks Investment Research upgraded Summit Therapeutics PLC from a hold rating to a buy rating and set a $7.00 target price for the company in a research report on Wednesday, September 14th. Oppenheimer Holdings Inc. restated an outperform rating and set a $28.00 target price on shares of Summit Therapeutics PLC in a research report on Wednesday, October 5th. HC Wainwright initiated coverage on Summit Therapeutics PLC in a research report on Friday, September 16th. They issued a buy rating and a $26.00 price objective for the company. Finally, Janney Montgomery Scott initiated coverage on Summit Therapeutics PLC in a research report on Tuesday, June 21st. They issued a buy rating for the company. Six research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $23.80.
Summit Therapeutics PLC (NASDAQ:SMMT) opened at 11.92 on Wednesday. Summit Therapeutics PLC has a 52-week low of $4.26 and a 52-week high of $19.75. The company has a 50 day moving average price of $8.02 and a 200-day moving average price of $7.80. The firm’s market cap is $146.54 million.
An institutional investor recently raised its position in Summit Therapeutics PLC stock. AXA boosted its position in Summit Therapeutics PLC (NASDAQ:SMMT) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 382,705 shares of the company’s stock after buying an additional 5,500 shares during the period. AXA owned about 3.12% of Summit Therapeutics PLC worth $2,989,000 as of its most recent SEC filing. Institutional investors own 23.43% of the company’s stock.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.